Published in Crit Care Med on July 01, 1997
Understanding the inflammatory cytokine response in pneumonia and sepsis: results of the Genetic and Inflammatory Markers of Sepsis (GenIMS) Study. Arch Intern Med (2007) 5.65
Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood (2011) 5.61
Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nat Rev Drug Discov (2012) 4.40
Receptors, mediators, and mechanisms involved in bacterial sepsis and septic shock. Clin Microbiol Rev (2003) 3.70
Pathophysiology of sepsis. Am J Pathol (2007) 3.19
The next generation of sepsis clinical trial designs: what is next after the demise of recombinant human activated protein C?*. Crit Care Med (2014) 3.17
Inflammasome-regulated cytokines are critical mediators of acute lung injury. Am J Respir Crit Care Med (2012) 2.92
IL-1 receptor antagonist ameliorates inflammasome-dependent alcoholic steatohepatitis in mice. J Clin Invest (2012) 2.64
Targeting interleukin-1 in heart disease. Circulation (2013) 2.52
A randomised phase II study of interleukin-1 receptor antagonist in acute stroke patients. J Neurol Neurosurg Psychiatry (2005) 2.41
Lethal inflammasome activation by a multidrug-resistant pathobiont upon antibiotic disruption of the microbiota. Nat Med (2012) 2.20
Immunopathologic alterations in murine models of sepsis of increasing severity. Infect Immun (1999) 2.13
Anti-inflammatory therapies to treat sepsis and septic shock: a reassessment. Crit Care Med (1997) 2.00
Interleukin-1 Receptor Blockade Is Associated With Reduced Mortality in Sepsis Patients With Features of Macrophage Activation Syndrome: Reanalysis of a Prior Phase III Trial. Crit Care Med (2016) 1.76
Sepsis: multiple abnormalities, heterogeneous responses, and evolving understanding. Physiol Rev (2013) 1.72
Clinical practice guidelines for hospital-acquired pneumonia and ventilator-associated pneumonia in adults. Can J Infect Dis Med Microbiol (2008) 1.68
The NLRP3 inflammasome in health and disease: the good, the bad and the ugly. Clin Exp Immunol (2011) 1.56
Cytokines in sepsis: potent immunoregulators and potential therapeutic targets--an updated view. Mediators Inflamm (2013) 1.54
A functional synonymous coding variant in the IL1RN gene is associated with survival in septic shock. Am J Respir Crit Care Med (2014) 1.53
Delayed administration of interleukin-1 receptor antagonist protects against transient cerebral ischaemia in the rat. Br J Pharmacol (2003) 1.50
Immunoparalysis and adverse outcomes from critical illness. Pediatr Clin North Am (2008) 1.47
Glyburide is anti-inflammatory and associated with reduced mortality in melioidosis. Clin Infect Dis (2011) 1.45
Early lactate clearance is associated with biomarkers of inflammation, coagulation, apoptosis, organ dysfunction and mortality in severe sepsis and septic shock. J Inflamm (Lond) (2010) 1.44
Modeling sepsis in the laboratory: merging sound science with animal well-being. Comp Med (2008) 1.42
A potential therapeutic role for P2X7 receptor (P2X7R) antagonists in the treatment of inflammatory diseases. Expert Opin Investig Drugs (2011) 1.39
CD40 and CD80/86 act synergistically to regulate inflammation and mortality in polymicrobial sepsis. Am J Respir Crit Care Med (2007) 1.37
Randomized study of the benefits of preoperative corticosteroid administration on the postoperative morbidity and cytokine response in patients undergoing surgery for esophageal cancer. Ann Surg (2002) 1.31
Hemorrhagic shock activation of NLRP3 inflammasome in lung endothelial cells. J Immunol (2011) 1.25
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2006. Ann Rheum Dis (2006) 1.25
Myeloid commitment shifts toward monocytopoiesis after thermal injury and sepsis. Ann Surg (2001) 1.24
Heat shock protein 90 inhibitors prolong survival, attenuate inflammation, and reduce lung injury in murine sepsis. Am J Respir Crit Care Med (2007) 1.24
Animal models of sepsis. Virulence (2013) 1.22
Sepsis-induced cardiomyopathy. Curr Cardiol Rev (2011) 1.21
Sepsis-induced cardiomyopathy: a review of pathophysiologic mechanisms. Heart Fail Rev (2010) 1.18
Differential role for CD80 and CD86 in the regulation of the innate immune response in murine polymicrobial sepsis. PLoS One (2009) 1.17
The changing immune system in sepsis: is individualized immuno-modulatory therapy the answer? Virulence (2013) 1.15
CD40 contributes to lethality in acute sepsis: in vivo role for CD40 in innate immunity. Infect Immun (2003) 1.15
Selective iNOS inhibition for the treatment of sepsis-induced acute kidney injury. Nat Rev Nephrol (2009) 1.14
Interleukin-3 amplifies acute inflammation and is a potential therapeutic target in sepsis. Science (2015) 1.14
Novel approaches to minimize ventilator-induced lung injury. BMC Med (2013) 1.07
The role of natural killer cells in sepsis. J Biomed Biotechnol (2011) 1.02
Treating rheumatological diseases and co-morbidities with interleukin-1 blocking therapies. Rheumatology (Oxford) (2015) 1.01
Inhibition of c-Jun-N-terminal kinase increases cardiac peroxisome proliferator-activated receptor alpha expression and fatty acid oxidation and prevents lipopolysaccharide-induced heart dysfunction. J Biol Chem (2011) 1.00
Interleukin 5 is protective during sepsis in an eosinophil-independent manner. Am J Respir Crit Care Med (2012) 1.00
Potential therapeutic uses of interleukin 1 receptor antagonists in human diseases. Ann Rheum Dis (2002) 0.99
Inhalation injury severity and systemic immune perturbations in burned adults. Ann Surg (2013) 0.99
Mouse eosinophils possess potent antibacterial properties in vivo. Infect Immun (2009) 0.99
Recombinant human interleukin-1 receptor antagonist in severe traumatic brain injury: a phase II randomized control trial. J Cereb Blood Flow Metab (2014) 0.97
Lymphocytes, apoptosis and sepsis: making the jump from mice to humans. Crit Care (2009) 0.95
Heme cytotoxicity and the pathogenesis of immune-mediated inflammatory diseases. Front Pharmacol (2012) 0.94
Lack of evidence for qualitative treatment by disease severity interactions in clinical studies of severe sepsis. Crit Care (2005) 0.93
Glibenclamide reduces pro-inflammatory cytokine production by neutrophils of diabetes patients in response to bacterial infection. Sci Rep (2013) 0.91
Sepsis: links between pathogen sensing and organ damage. Curr Pharm Des (2008) 0.90
Effects of propofol on early and late cytokines in lipopolysaccharide-induced septic shock in rats. J Biomed Res (2010) 0.88
Gene set enrichment analysis identifies key innate immune pathways in primary graft dysfunction after lung transplantation. Am J Transplant (2013) 0.87
A clinical evaluation committee assessment of recombinant human tissue factor pathway inhibitor (tifacogin) in patients with severe community-acquired pneumonia. Crit Care (2009) 0.86
Therapeutic strategies in inflammasome mediated diseases of the liver. J Hepatol (2012) 0.85
Associations between interleukin-1 gene polymorphisms and sepsis risk: a meta-analysis. BMC Med Genet (2014) 0.85
Sepsis and septic shock. Nat Rev Dis Prim (2016) 0.85
Evasion of inflammasome activation by microbial pathogens. J Clin Invest (2015) 0.84
Management of sepsis in neutropenic patients: 2014 updated guidelines from the Infectious Diseases Working Party of the German Society of Hematology and Medical Oncology (AGIHO). Ann Hematol (2014) 0.84
Pathophysiology of sepsis-related cardiac dysfunction: driven by inflammation, energy mismanagement, or both? Curr Heart Fail Rep (2015) 0.84
Critical care trial design and interpretation: a primer. Crit Care Med (2010) 0.83
ARF6 inhibition stabilizes the vasculature and enhances survival during endotoxic shock. J Immunol (2014) 0.83
Lipopolysaccharide desensitizes monocytes-macrophages to CD40 ligand stimulation. Immunology (2007) 0.82
An expanding role for interleukin-1 blockade from gout to cancer. Mol Med (2014) 0.82
The TFPI-2 derived peptide EDC34 improves outcome of gram-negative sepsis. PLoS Pathog (2013) 0.82
Toll-like receptor 2 deficiency results in impaired antibody responses and septic shock during Borrelia hermsii infection. Infect Immun (2010) 0.82
The anti-inflammatory effect of combined complement and CD14 inhibition is preserved during escalating bacterial load. Clin Exp Immunol (2015) 0.82
RKIP contributes to IFN-γ synthesis by CD8+ T cells after serial TCR triggering in systemic inflammatory response syndrome. J Immunol (2013) 0.81
CD1d- and MR1-Restricted T Cells in Sepsis. Front Immunol (2015) 0.81
Distinctive cytokines as biomarkers predicting fatal outcome of severe Staphylococcus aureus bacteremia in mice. PLoS One (2013) 0.81
Binge alcohol consumption aggravates oxidative stress and promotes pathogenesis of NASH from obesity-induced simple steatosis. Mol Med (2014) 0.81
Increasing the efficacy of anti-inflammatory agents used in the treatment of sepsis. Eur J Clin Microbiol Infect Dis (2003) 0.81
Reduced plasma ghrelin levels on day 1 after esophagectomy: a new predictor of prolonged systemic inflammatory response syndrome. Surg Today (2012) 0.80
Epithelial transport during septic acute kidney injury. Nephrol Dial Transplant (2013) 0.80
Therapeutic Administration of a Monoclonal Anti-Il-1β Antibody Protects Against Experimental Melioidosis. Shock (2016) 0.80
Blood gene expression profiling in pediatric systemic lupus erythematosus and systemic juvenile idiopathic arthritis: from bench to bedside. Pediatr Rheumatol Online J (2014) 0.79
Leukocyte activity in patients with ST-segment elevation acute myocardial infarction treated with anakinra. Mol Med (2014) 0.79
Blocking IL-1beta to slow down progression of ALS? Proc Natl Acad Sci U S A (2010) 0.79
Wnt5A/Ryk signaling critically affects barrier function in human vascular endothelial cells. Cell Adh Migr (2016) 0.79
Characterization of the MMP/TIMP Imbalance and Collagen Production Induced by IL-1β or TNF-α Release from Human Hepatic Stellate Cells. PLoS One (2016) 0.79
Microbiological and inflammatory effects of murine recombinant interleukin-10 in two models of polymicrobial peritonitis in rats. Infect Immun (1999) 0.78
Cecal ligation and puncture accelerates development of ventilator-induced lung injury. Am J Physiol Lung Cell Mol Physiol (2014) 0.78
Immune-modulating therapy in acute pancreatitis: fact or fiction. World J Gastroenterol (2014) 0.78
Rationale and study design for a phase I/IIa trial of anakinra in children with Kawasaki disease and early coronary artery abnormalities (the ANAKID trial). Contemp Clin Trials (2016) 0.77
New strategy for sepsis: Targeting a key role of platelet-neutrophil interaction. Burns Trauma (2014) 0.77
Sepsis induced by cecal ligation and puncture. Methods Mol Biol (2013) 0.77
Low-dose cyclophosphamide improves survival in a murine treatment model of sepsis. Shock (2015) 0.77
The immune response: targets for the treatment of severe sepsis. Int J Inflam (2012) 0.77
alpha-GlcNAc-1-->2-alpha-glc, the Salmonella homologue of a conserved lipopolysaccharide motif in the Enterobacteriaceae, elicits broadly cross-reactive antibodies. Infect Immun (1998) 0.77
Therapeutic targeting of the inflammome. Biochem Pharmacol (2014) 0.76
New means to assess neonatal inflammatory brain injury. J Neuroinflammation (2015) 0.76
Towards precision medicine for sepsis patients. Crit Care (2017) 0.76
Effect of intraperitoneal application of an endotoxin inhibitor on survival time in a laparoscopic model of peritonitis in rats. World J Surg (2005) 0.76
Insights and limits of translational research in critical care medicine. Ann Intensive Care (2015) 0.76
The regulatory role of immunosuppressants on immune abnormalities in acute pancreatitis. Biomed Rep (2013) 0.76
Protective Effects of Huang-Lian-Jie-Du-Tang against Polymicrobial Sepsis Induced by Cecal Ligation and Puncture in Rats. Evid Based Complement Alternat Med (2013) 0.76
Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med (2001) 27.70
HMG-1 as a late mediator of endotoxin lethality in mice. Science (1999) 17.72
Shock and tissue injury induced by recombinant human cachectin. Science (1986) 16.24
Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature (1988) 13.42
Serial evaluation of the SOFA score to predict outcome in critically ill patients. JAMA (2001) 10.03
Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group. N Engl J Med (1991) 9.99
Standardized surgery for colonic cancer: complete mesocolic excision and central ligation--technical notes and outcome. Colorectal Dis (2009) 5.72
Plasma cytokine and endotoxin levels correlate with survival in patients with the sepsis syndrome. Ann Intern Med (1993) 5.46
Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group. N Engl J Med (1996) 5.25
Macrophages secrete a novel heparin-binding protein with inflammatory and neutrophil chemokinetic properties. J Exp Med (1988) 5.16
Randomised double-blind placebo-controlled trial of SPf66 malaria vaccine in children in northwestern Thailand. Shoklo SPf66 Malaria Vaccine Trial Group. Lancet (1996) 4.90
Acute renal failure in the ICU: risk factors and outcome evaluated by the SOFA score. Intensive Care Med (2000) 4.74
Antibodies to cachectin/tumor necrosis factor reduce interleukin 1 beta and interleukin 6 appearance during lethal bacteremia. J Exp Med (1989) 4.66
Treatment of gram-negative bacteremia and shock with human antiserum to a mutant Escherichia coli. N Engl J Med (1982) 4.28
Cachectin/tumor necrosis factor induces lethal shock and stress hormone responses in the dog. Surg Gynecol Obstet (1987) 4.18
Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock. NORASEPT II Study Group. Lancet (1998) 4.05
Effect of iron on yields of exotoxin A in cultures of Pseudomonas aeruginosa PA-103. Infect Immun (1978) 4.01
Symptoms of anxiety and depression in family members of intensive care unit patients: ethical hypothesis regarding decision-making capacity. Crit Care Med (2001) 3.98
Toxin A-deficient mutants of Pseudomonas aeruginosa PA103: isolation and characterization. Infect Immun (1980) 3.95
The use of maximum SOFA score to quantify organ dysfunction/failure in intensive care. Results of a prospective, multicentre study. Working Group on Sepsis related Problems of the ESICM. Intensive Care Med (1999) 3.93
A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. N Engl J Med (1987) 3.89
Corticosteroid treatment for sepsis: a critical appraisal and meta-analysis of the literature. Crit Care Med (1995) 3.74
ATS/ERS/WASOG statement on sarcoidosis. American Thoracic Society/European Respiratory Society/World Association of Sarcoidosis and other Granulomatous Disorders. Sarcoidosis Vasc Diffuse Lung Dis (1999) 3.69
Utility of a lung biopsy for the diagnosis of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2001) 3.69
Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor alpha in vitro and in vivo. Proc Natl Acad Sci U S A (1992) 3.61
Immediate coronary angiography in survivors of out-of-hospital cardiac arrest. N Engl J Med (1997) 3.53
Association of TNF2, a TNF-alpha promoter polymorphism, with septic shock susceptibility and mortality: a multicenter study. JAMA (1999) 3.51
Sepsis syndrome: a valid clinical entity. Methylprednisolone Severe Sepsis Study Group. Crit Care Med (1989) 3.41
The relation of pneumothorax and other air leaks to mortality in the acute respiratory distress syndrome. N Engl J Med (1998) 3.40
An overview of mortality risk prediction in sepsis. Crit Care Med (1995) 3.37
Serial blood lactate levels can predict the development of multiple organ failure following septic shock. Am J Surg (1996) 3.31
Cytokine appearance in human endotoxemia and primate bacteremia. Surg Gynecol Obstet (1988) 3.30
Has the mortality of septic shock changed with time. Crit Care Med (1998) 3.29
Spectrum of hantavirus infection: hemorrhagic fever with renal syndrome and hantavirus pulmonary syndrome. Annu Rev Med (1999) 3.24
Erythropoietin response is blunted in critically ill patients. Intensive Care Med (1997) 3.20
Analysis of p53 expression in human tumours: an antibody raised against human p53 expressed in Escherichia coli. J Cell Sci (1992) 3.18
PDGF-regulated rab4-dependent recycling of alphavbeta3 integrin from early endosomes is necessary for cell adhesion and spreading. Curr Biol (2001) 3.13
Toxin inhibitors of protein synthesis: production, purification, and assay of Pseudomonas aeruginosa toxin A. Methods Enzymol (1979) 3.10
Germline transformation of the silkworm Bombyx mori L. using a piggyBac transposon-derived vector. Nat Biotechnol (2000) 3.09
Incidence of exotoxin production by Pseudomonas species. Infect Immun (1977) 3.08
Localization of plasmid loci necessary for the entry of Shigella flexneri into HeLa cells, and characterization of one locus encoding four immunogenic polypeptides. J Gen Microbiol (1987) 3.05
Hypothermia in the sepsis syndrome and clinical outcome. The Methylprednisolone Severe Sepsis Study Group. Crit Care Med (1992) 2.99
Procalcitonin used as a marker of infection in the intensive care unit. Crit Care Med (1999) 2.93
Role of pili in the adherence of Pseudomonas aeruginosa to injured tracheal epithelium. Infect Immun (1984) 2.92
A randomised comparison of strategies for reducing infective complications of induced abortion. Br J Obstet Gynaecol (1998) 2.86
Influence of an anti-tumor necrosis factor monoclonal antibody on cytokine levels in patients with sepsis. The CB0006 Sepsis Syndrome Study Group. Crit Care Med (1993) 2.84
Iatrogenic complications in adult intensive care units: a prospective two-center study. Crit Care Med (1993) 2.84
Sepsis: a new hypothesis for pathogenesis of the disease process. Chest (1997) 2.84
Serum cytokine levels in human septic shock. Relation to multiple-system organ failure and mortality. Chest (1993) 2.79
Growth of continental-scale metro-agro-plexes, regional ozone pollution, and world food production. Science (1994) 2.76
Sedative and analgesic practice in the intensive care unit: the results of a European survey. Br J Anaesth (2001) 2.75
EVALUATION OF A DYNAMIC METHOD FOR CALIBRATION OF DYE DILUTION CURVES. Br Heart J (1963) 2.75
A profile of European intensive care unit physiotherapists. European Society of Intensive Care Medicine. Intensive Care Med (2000) 2.72
Effects of accidental trauma on cytokine and endotoxin production. Crit Care Med (1993) 2.67
Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome: a randomized, open-label, placebo-controlled multicenter trial. Crit Care Med (1994) 2.66
Acute gastric volvulus: pathogenesis, diagnosis, and treatment. Am J Gastroenterol (1993) 2.59
Randomized, placebo-controlled trial of the anti-tumor necrosis factor antibody fragment afelimomab in hyperinflammatory response during severe sepsis: The RAMSES Study. Crit Care Med (2001) 2.56
Methylene blue administration in septic shock: a clinical trial. Crit Care Med (1995) 2.50
A second large controlled clinical study of E5, a monoclonal antibody to endotoxin: results of a prospective, multicenter, randomized, controlled trial. The E5 Sepsis Study Group. Crit Care Med (1995) 2.48
Abacterial Pyuria. Br Med J (1945) 2.47
Predictive value of microalbuminuria in medical ICU patients: results of a pilot study. Chest (2001) 2.43
Safety, immunogenicity, and efficacy of live attenuated Vibrio cholerae O139 vaccine prototype. Lancet (1995) 2.43
Interleukin-6 gene-deficient mice show impaired defense against pneumococcal pneumonia. J Infect Dis (1997) 2.39
French intensivists do not apply American recommendations regarding decisions to forgo life-sustaining therapy. Crit Care Med (2001) 2.39
Randomized, prospective trial of pressure-limited versus volume-controlled ventilation in severe respiratory failure. Crit Care Med (1994) 2.35
The hepatosplanchnic area is not a common source of lactate in patients with severe sepsis. Crit Care Med (2001) 2.34
An open-label dose escalation study of the nitric oxide synthase inhibitor, N(G)-methyl-L-arginine hydrochloride (546C88), in patients with septic shock. Glaxo Wellcome International Septic Shock Study Group. Crit Care Med (1999) 2.33
Relationship between plasma levels of lipopolysaccharide (LPS) and LPS-binding protein in patients with severe sepsis and septic shock. J Infect Dis (1999) 2.32
Physiotherapy for adult patients with critical illness: recommendations of the European Respiratory Society and European Society of Intensive Care Medicine Task Force on Physiotherapy for Critically Ill Patients. Intensive Care Med (2008) 2.31
Immunohistochemical detection of p53 protein in mammary carcinoma: an important new independent indicator of prognosis? Hum Pathol (1993) 2.27
A system for the measurement of respiratory and acid-base parameters in blood. Br J Anaesth (1965) 2.26
Blood lactate levels are superior to oxygen-derived variables in predicting outcome in human septic shock. Chest (1991) 2.25
Cross-reactivity of Neisseria gonorrhoeae and Neisseria meningitidis and the nature of antigens involved in the bactericidal reaction. J Infect Dis (1974) 2.24
An improved plasmid DNA expression vector for direct injection into skeletal muscle. Hum Gene Ther (1996) 2.23
Is the pulmonary artery catheter misused? A European view. Crit Care Med (1998) 2.23
Isolation and characterization of a high-molecular-weight polysaccharide from the slime of Pseudomonas aeruginosa. Infect Immun (1978) 2.22
Protective efficacy of oral whole-cell/recombinant-B-subunit cholera vaccine in Peruvian military recruits. Lancet (1994) 2.16
The importance of the K1 capsule in invasive infections caused by Escherichia coli. J Infect Dis (1984) 2.14